2023年2月6日

通过SPAC ipo融资06.02.2023大肆宣传了幻灭。许多特定目标被清算。但是好消息是至少的SPAC眼想在纳斯达克上市。去年10月理事眼和纳斯达克上市收购欧洲生物技术公司(EBAC)宣布,他们已经进入最终企业合并协议。该交易预计将在2023年H1完成。8 - k文件中EBAC透露,管道(私人投资私人股本)将增加。额外获得后续初始管融资1500万美元,2023年1月26日EBAC进入额外订购协议。随后管投资者同意认购时间累计购买788500 EBAC普通股每股10.00美元的收购价格,总总销售收入为7885000美元。10月,眼也宣布进入可转换贷款协议与某些现有的股票持有者。2023年1月26日,眼和一个额外的银行最初的银行一起进入可转换贷款协议在实质上相同的形式作为初始可转换贷款协议。 The Additional Lender has granted Oculis a right to receive a convertible loan with certain conversion rights in an aggregate amount of $7,000,000. Oculis is a global biopharmaceutical company developing treatments to save sight and improve eye care with breakthrough innovations. The company is currently advancing its diversified product portfolio, which includes three clinical-stage product candidates (OC-1, OC-2 and OC-5). OCS-01 is currently in Phase 3 development, globally (USA, EU, CN) for DME (Diabetic Macular Edema) with the potential to become the first non-invasive, topical eye drop for a back of the eye disease. OCS-01 is also in Phase 3 development in the USA for the treatment of inflammation and pain following cataract surgery, which would, if approved, potentially be the first once-a-day steroid for this indication. (Press release / SK)